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After ischemia-reperfusion injury (IRI), kidney tu-
bules show activated transforming growth factor 
(TGF-) signaling and increased expression of profi-
brotic peptides, platelet-derived growth factor-B
(PDGF-B) and connective tissue growth factor (CTGF).
If tubule repair after IRI is incomplete, sustained para-
crine activity of these peptides can activate interstitial
fibroblast progenitors and cause fibrosis. We show
that lysophosphatidic acid (LPA), a ubiquitous phos-
pholipid that is increased at sites of injury and inflam-
mation, signals through LPA2 receptors and Gq pro-
teins of cultured proximal tubule cells to transactivate
latent TGF- in a Rho/Rho-kinase and v6 integrin-
dependent manner. Active TGF- peptide then initi-
ates signaling to increase the production and secre-
tion of PDGF-B and CTGF. In a rat model of IRI,
increased TGF- signaling that was initiated early dur-
ing reperfusion did not subside during recovery, but
progressively increased, causing tubulointerstitial fi-
brosis. This was accompanied by correspondingly in-
creased LPA2 and 6 integrin proteins and elevated
tubule expression of TGF-1, together with PDGF-B
and CTGF. Treatment with a pharmacological TGF-
type I receptor antagonist suppressed TGF- signal-
ing, decreased the expression of6 integrin, PDGF-B, and
CTGF, and ameliorated fibrosis. We suggest that LPA-initi-
ated autocrine signaling is a potentially important mech-
1236anism that gives rise to paracrine profibrotic signaling in
injured kidney tubule cells. (Am J Pathol 2012, 181:1236–
1249; http://dx.doi.org/10.1016/j.ajpath.2012.06.035)
Kidney tubules recovering from ischemia-reperfusion in-
jury (IRI) exhibit increased transforming growth factor 
(TGF-) signaling1–4 that produces fibrosis.1,3–6 The ex-
pression of TGF- and its receptors is increased in re-
generating proximal tubules during recovery after IRI,
suggesting the operation of an amplified autocrine sig-
naling loop.1,7 The mechanism of initiation is unknown.
However, there must be early steps that trigger TGF-
signaling which then gives rise to sustained and ampli-
fied signaling by undefined feed-forward mechanisms
and cross talk with other pathways. Increased conversion
of latent TGF- to active peptide is such a required and
important early step.8 TGF- is secreted as an inactive
complex with latency-associated peptide (LAP). Several
physical, chemical, and enzymatic processes can con-
vert latent TGF- to active peptide.8–12 Among these
processes, activation caused by the binding of Arg-Gly-
Asp (RGD) domains in latent TGF-1 or TGF-3 to integ-
rins is particularly relevant. Several integrins bind and
activate TGF-, but this action of v6 integrin is re-
stricted to epithelial cells.13
A role for the v6 integrin has been shown in several
disease models.10,14–17 TGF- activation by v6 contrib-
utes to lung injury and fibrosis, an action that is triggered by
G-protein–coupled receptor (GPCR) ligands, lysophospha-
tidic acid (LPA) and thrombin.15,18 It seemed likely that a
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naling after IRI that, if sustained, causes fibrosis. v6
Integrin is overexpressed in tubule epithelium of human
kidneys with chronic kidney disease16,19 and contributes
to renal fibrosis in mouse models of Alport syndrome and
ureteral obstruction.16,17 A GPCR and integrin-mediated
mechanism seems likely to account for TGF- activa-
tion and fibrosis in these contexts, as shown for the
lung.15,18 GPCR ligands reported to bear some rela-
tionship to renal injury and fibrosis and/or TGF- sig-
naling in kidney cells include angiotensin II, LPA, sph-
ingosine-1-phosphate (S1P), and thrombin.17,20–28
How these ligands affect injury outcomes in kidneys or
TGF- signaling in renal cells is largely unexplored. As
an exception, angiotensin II increased TGF- produc-
tion by proximal tubules through epidermal growth fac-
tor receptor transactivation and downstream signaling
by extracellular signal–regulated kinase.21
We surmised that, among the myriad regenerative sig-
nals triggered by IRI, there are some with potential to trans-
activate TGF-. The GPCR ligands, LPA, S1P, thrombin,
adenosine, and angiotensin II, are implicated in the devel-
opment of acute kidney injury after ischemia.26,29–33
Whether they are also involved in repair, as reported
for LPA and thrombin in the lung,15,18 is unknown. We
asked if one such ligand, LPA, transactivates TGF- sig-
naling in cultured tubule cells. We show that LPA acti-
vates latent TGF- through a Gq/11-mediated Rho and
v6-dependent process in proximal tubule cells, as in
lung epithelium. Active TGF-, produced in an LPA-de-
pendent manner, then drives the secretion of profibrotic
peptides, platelet-derived growth factor-B (PDGF-B) and
connective tissue growth factor (CTGF). Pursuant to our
earlier experiments in vivo,3,6 we found that persistently
dedifferentiated tubules associated with fibrosis after IRI
display increased TGF- signaling and increased ex-
pression of PDGF-B and CTGF. Furthermore, LPA2 re-
ceptor and v6 integrin proteins were markedly ele-
vated in kidney tissue in the same time frame that TGF-,
PDGF-B, and CTGF expression was also increased. Con-
sidered in the context of our findings in cultured cells,
and reported observations on lung epithelium,15,18 these
observations in vivo provide suggestive, but persuasive,
evidence that GPCR signaling by LPA is a possible prox-
imate trigger for profibrotic TGF- signaling in tubules
regenerating after IRI.
Materials and Methods
Antibodies and Reagents
Antibody sources were as follows: anti-phospho-Smad2
(S465/467) from Cell Signaling, Inc. Cat. No. 3108 (Dan-
vers, MA); anti-Smad2/3 from BD transduction, Cat. No.
610842 (San Diego, CA); and anti-Smad2 from Epitom-
ics, Cat. No. 1736 (Burlingame, CA); v6 antibodies
Mab 6.3G9 and ch2A1 were produced as described
previously16,34; anti-LPA2 was from Abgent, Inc., Cat. No.
AP6140a (San Diego, CA); anti–TGF- was from R&D
systems, Inc., Cat. No. AB-100-NA (Minneapolis, MN)and AbD Serotec, Cat. No. AHP1734 (Raleigh, NC); anti-
PDGF-B was from LS Bio, Cat. No. LS-B4182 (Seattle,
WA); anti-CTGF was from Santa Cruz, Cat. No. sc14939
(Santa Cruz, CA); anti-vimentin was from Neomarkers/
Thermo Scientific Lab Vision, Cat. No. MS129 (Fremont,
CA). Secondary antibodies conjugated with HRP were
from Jackson ImmunoResearch Labs, Cat. Nos. 715-035-
152 and 715-035-150 (West Grove, PA). Secondary an-
tibodies conjugated with Alexa dyes 488, 568 and 647
were from Invitrogen, Carlsbad, CA. Sources of other
reagents were as follows: SD-208; 2-[(5-Chloro-2-fluoro-
phenyl)pteridin-4-yl]pyridin-4-yl amine, from SCIOS, Inc.,
(now subsidiary of Johnson and Johnson, New Bruns-
wick, NJ); SB431542, Ki16425 and Sphingosylphospho-
rylcholine from Sigma-Aldrich Cat. No. S4317, k0639 and
S4275 (St. Louis, MO). Latent TGF-1 from R&D systems,
Cat. No. 299-LT (Minneapolis, MN), LPA from Enzo Life
Sciences, Cat. No. LP100 (Plymouth Meeting, PA),
HLZ-56 [a kind gift from Glenn D. Prestwich (University of
Utah)] was also purchased from Echelon Biosciences,
Cat. No. L-7416 (Salt Lake City, UT), Sphingosine-1-
phosphate (S1P) from Cayman chemical, Cat. No. 62570
(Ann Arbor, MI), BIM46174 was a kind gift from Grégoire
P. Prévost (IPSEN-Institut Henri Beaufour), Pertussis toxin
from List biological laboratories, Cat. No. 179A (Camp-
bell, CA), GM 6001 and GM 6001 Negative control from
EMD Chemicals, Cat. Nos. 364205 and # 364210 respec-
tively (Rockland, MA).
Cell Culture, Plasmids, and Vectors
Boston University mouse proximal tubule cells (BUMPTs;
clone 306; obtained from Drs. Wilfred Lieberthal and
John Schwartz, Boston University School of Medicine,
Boston, MA) and human proximal convoluted tubule cells
(HPCTs; obtained from Dr. Ulrich Hopfer, Case Western
Reserve University, Cleveland, OH) were grown at 37°C
in Dulbecco’s modified Eagle’s medium with 10% fetal
calf serum (FCS) or in serum-free Dulbecco’s modified
Eagle’s medium (DMEM)/Ham’s F12 medium with insulin
(10 g/mL), transferrin (5 g/mL), Na selenite (6.7 g/
mL), and dexamethasone (4 g/mL). BUMPT cells were
transfected with p3TP-Luc35 (obtained from Dr. Joan
Massague, Memorial Sloan-Kettering Cancer Center,
New York, NY), (CAGA)12-Luc, or 2 X ARE-Luc with
pCMV-hFAST136,37 (obtained from Dr. Susumu Itoh, Uni-
versity of Tsukuba, Tsukuba, Japan), together with
pCMV-Neo or Hygro. Stably transfected cells were se-
lected with G418 or hygromycin and clones assayed for
luciferase activity after treatment with and without TGF-
(2 ng/mL). Mouse proximal tubule cells were grown in
primary culture, as previously described.3 The growth
medium was modified from published formulations and
contained bovine serum albumin (0.5%), insulin (10 g/
mL), epidermal growth factor (10 ng/mL), transferrin (5
g/mL), Na selenite (6.7 g/mL), dexamethasone (4 g/
mL), and l-ascorbic acid-2-phosphate (50 mol/L). Cells
were used at first passage. HK-2 cells (CRL-2190; ATCC,
Manassas, VA) of human proximal tubular origin were
grown in DMEM/Ham’s F12 medium (Gibco, Invitrogen,
Grand Island, NY) containing 5 mmol/L glucose, supple-
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(10 ng/mL), transferrin (5 g/mL), Na selenite (6.7 g/
mL), and dexamethasone (4 g/mL), supplemented with
10% FCS. G-protein C-terminal peptide minigene vec-
tors38 (obtained from Dr. Heidi Hamm, Vanderbilt
University Medical Center, Nashville, TN) were trans-
fected using Fugene reagent. The LPA2-specific TRC
shRNA-pLKO.1 plasmid construct (TRC number
TRCN0000234209, clone ID NM_020028.3-1013s21c1,
catalogue number NM_020028; Sigma-Aldrich) or a
negative control scramble shRNA-pLKO.1 construct
was cotransfected with the packaging plasmid into
293T cells using Fugene HD Reagent (catalogue number
04709705001; Roche Applied Science, Indianapolis,
IN). The short hairpin RNA (shRNA) target sequence
for LPA2 was as follows: 5=-CCGGTGGTCAATGC-
AGTGGTATATTCTCGAGAATATACCACTGCATTGACC-
ATTTTTG-3=. Culture supernatants containing lentiviral
particles were collected 48 hours after transfection and
filtered through 0.45 mol/L filters. BUMPT cells were
transduced with viral supernatant in the presence of 5
g/mL polybrene. After 48 hours, cells were replenished
with fresh medium containing 1 g/mL puromycin. Cells
were maintained in puromycin medium for selection of
stably transfected cells.
Growth and Wounding of Cultured Proximal
Tubule Monolayer Cells
BUMPT cells were grown until confluent contact inhi-
bition and differentiation in 21-cm2 culture dishes. The
monolayer cells were wounded in concentric circular
swaths with preserved strips of cells in between by
using a device consisting of a flat, approximately 21-
cm2 etched rubber disk with a series of alternating
0.2-mm-wide concentric grooves and 0.8-mm-wide un-
etched ridges. Approximately 80% to 90% of cell mass
was removed from confluent BUMPT cultures by
wounding. Dedifferentiation, migration, proliferation,
and modulations of autocrine TGF- signaling in the
remaining cells were described.3,39 Active TGF- in
conditioned medium was measured using mink lung
epithelial cells stably transfected with a truncated plas-
minogen activator inhibitor-1 promoter-luciferase fu-
sion plasmid40 (obtained from Dr. Daniel Rifkin, New
York University Langone School of Medicine, New
York, NY).
Charcoal Treatment of FCS and Serum Lipid
Extraction
Charcoal-stripped FCS (C-FCS) was prepared as previ-
ously described.41 In brief, 10 mL of FCS was incubated
with 1 g of activated charcoal (Sigma-Aldrich) overnight
at 4°C. After centrifugation at 2000 g for 10 minutes, the
supernatant was filtered through a 0.22 mol/L cellulose
acetate filter. Serum lipids were extracted as previously
described.42 In brief, 1 mL of serum was added into 15
mL of MeOH in a glass tube. After vortex mixing and
incubation on ice for 10 minutes, the mixture was cen-trifuged (at 10,000  g, for 5 minutes, at room temper-
ature), and the supernatant was collected and dried.
The extract was redissolved in 6 mL of CHCl3:MeOH
(1:1) and centrifuged. The supernatant was dried and
saved.
Ischemia-Reperfusion Injury
Male Sprague-Dawley rats, weighing approximately
250 g body weight, were used for IRI studies, as pre-
viously described.3 The left renal vascular pedicle was
clamped with aneurysm clips (Roboz Surgical Instru-
ments Co., Gaithersburg, MD) under isoflurane anes-
thesia on a heated table. The pedicle was dissected,
but not clamped, in controls. Right kidneys were re-
moved in both groups. Clamps were removed after 45
minutes, and the abdominal incision was closed. Body
temperature was maintained at 37°C. Blood samples
were obtained before surgery and daily to measure
serum creatinine by high-performance liquid chroma-
tography.43 At 4 hours after surgery and at 12 hourly
intervals, one group of rats received SD208 (60 mg/kg)
by gavage. SD208, a TGF- type I receptor antago-
nist,44 was suspended in 1% methylcellulose. Controls
received 1% methylcellulose. Treatments were contin-
ued for 4 days.
Histological, IHC, and Immunofluorescence
Analyses
Kidneys were fixed by vascular perfusion with periodic
acid–lysine–paraformaldehyde and processed for his-
tological, immunohistochemical (IHC), and immunoflu-
orescence (IF) analyses, as previously described.3,6
Western Blot Analysis
Kidneys were placed on a metal plate cooled by melt-
ing ice, sliced, and washed with cold PBS. The outer
stripe of outer medulla was dissected and flash frozen
in liquid nitrogen. Frozen tissue was ground under
liquid nitrogen and extracted with 2 SDS sample
buffer with protease and phosphatase inhibitors. Pro-
tein was measured by BCA assay. The equivalency of
protein loading was assessed by densitometry of indi-
vidual lanes of Coomassie Blue–stained gels and fur-
ther by loading controls. Cultured cells were extracted
with SDS sample buffer with protease and phospha-
tase inhibitors. Procedures for SDS-PAGE and Western
blot analysis were described.3
Real-Time RT-PCR
The expression of LPA receptors in BUMPT cells was
determined by quantitative real-time RT-PCR. Total
RNAs were purified from BUMPT cells using RNeasy
Mini kit (number 74104; Qiagen, Valencia, CA) and
were converted to cDNAs using a High Capacity cDNA
Reverse Transcription Kit (number 4368814; Life Tech-
nologies, Carlsbad). Real-time PCR with SYBR Green
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rescence detection was performed using an ABI Prism
7000 ABI PRISM 7000 Sequence Detection System (Ap-
plied Biosystems, Carlsbad, CA) with specific primers. The
following primers were used for LPA receptors: LPA1, 5=-
CATGGTGGCAATCTACGTCAA-3= (sense) and 5=-AGGC-
CAATCCAGCGAAGAA-3= (antisense); LPA2, 5=-TGTCT-
GACTGCACAGCTTGGA-3= (sense) and 5=-CTC-
ATGGAGTTTTCTGGTGCC-3= (antisense); LPA3, 5=-
GTACCTGAGCCCCCCATTG-3= (sense) and 5=-AAAC-
CCATGCGGAAACAACT-3= (antisense); LPA4, 5=-CCTTAC-
CAACATCTATGGGAGCAT-3= (sense) and 5=-TGGC-
CAGGAAACGATCCA-3= (antisense); and LPA5, 5=-
GGGGTGCTGATGAT-3= (sense) and 5=-TTCTGAGGG-
TAGTT-3= (antisense). Other primers used were as follows:
PDGF-B, 5=-CCACTCCATCCGCTCCTTT-3= (sense) and 5=-
AAGTCCAGCTCAGCCCCAT-5= (antisense); and CTGF,
5=-AGGACTGCAGCGCGCAATGT-3= (sense) and 5=-
GAGGCCCTTGTGTGGGTCGC-3= (antisense). Appro-
priate no-RT and nontemplate controls were included
in the PCR, and dissociation analysis was performed at
the end of each run to confirm the specificity of the
reaction. Relative levels of mRNA were calculated.Statistics
Tests were performed using paired Student t-tests and
analysis of variance. Comparisons were considered sig-
nificant at P  0.05.
Results
A Subpopulation of Regenerating Proximal
Tubules Show Persistently Increased Expression
of TGF-1, Nuclear Smad2, PDGF-B, and CTGF
After Ischemia-Reperfusion Injury of the Kidney
By using Western blot analysis, kidneys recovering from
IRI showed early increases of TGF-1 and Smad2 phos-
phorylation, consistent with previous reports.1–3 Subse-
quently, during more prolonged reperfusion, we found
that the increased TGF- expression and Smad phos-
phorylation did not subside, as might be expected if
repair was complete and normal tubule phenotype was
restored. Instead, the signals increased substantially by
14 days (Figure 1A). These increases coincided with the
development of tubulointerstitial fibrosis.3 By IHC, in-
Figure 1. Ischemia-reperfusion injury stimu-
lates TGF- signaling and induces profibrotic
peptide expression in renal proximal tubules. A:
SDS extracts of the outer stripe of the outer
medulla from normal control rats without sur-
gery (Normal Ctrl), renal IRI with or without
SD208 treatment at the indicated time after sur-
gery, and nephrectomized control (Nephr Ctrl)
at day 14 are immunoblotted for phospho-
Smad2, total Smad2/3, TGF-1, and CTGF. B, D,
and E: IHC staining of TGF-1, PDGF, and CTGF
in kidneys 14 days after right unilateral nephrec-
tomy (Nephr Cntrl), right unilateral nephrec-
tomy, and left kidney IRI with vehicle treatment
(IRI  Vehicle) or SD208 treatment (IRI 
SD208). C: Double- or triple-color confocal IF 14
days after surgery. Kidneys from nephrectomy
control, 14-day IRI  Vehicle, and 14-day IRI 
SD208 rats are stained for Smad2 (red), vimentin
(Vim; green), and DAPI (blue). Arrowheads,
Vimentin-positive regenerating proximal tubules
with nuclear Smad2. Scale bars: 100 m (IHC
images); 5 m (IF images). GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase.
1240 Geng et al
AJP October 2012, Vol. 181, No. 4creased tubule expression of TGF- at 14 days was accom-
panied by fibrosis (Figure 1B). By IF, dedifferentiated
vimentin-positive tubules in fibrotic tissue showed in-
creased staining and nuclear localization of Smad2 protein
(Figure 1C). TGF- signaling may stimulate the production
of profibrotic peptides, such as PDGF-B and CTGF. West-
ern blot analysis for PDGF-B was confounded by technical
issues related to the presence of PDGF-B in blood platelets
trapped in kidney tissue. After an early increase by 1 day of
IRI, kidney expression of CTGF subsided, but not to base-
line levels. The signal increased again by 14 days as fibro-
sis developed, concurrently with a similar increase in the
expression of TGF- (Figure 1A). By using IHC 14 days after
IRI, tubules associated with fibrosis showed intense immu-
noreactivity for PDGF-B and CTGF (Figure 1, D and E).
Treatment with the TGF- type I receptor antagonist,
SD208, did not modify the elevated expression of TGF-
that was seen 14 days after IRI (Figure 1, A and B), but
instead diminished Smad2 phosphorylation (Figure 1A), the
nuclear translocation of Smad2 protein (Figure 1C), and the
expression of both PDGF-B and CTGF (Figure 1, D and E),
and ameliorated the tubulointerstitial fibrosis that developed
otherwise.3 These data indicated that TGF- was overex-
pressed and TGF- signaling was up-regulated in proximal
tubule cells when renal fibrosis developed after renal IRI.
However, the mechanisms by which differentiated proximal
tubule cells transformed to a profibrotic phenotype express-
ing PDGF-B and CTGF after kidney injury were unknown.
LPA Is a Major Bioactive Lipid in Serum for
TGF- Signaling Stimulation
The results of our in vivo study, as shown in Figure 1, led
us to investigate the possible causative factors that drive
Figure 2. Serum lipids stimulate TGF- signaling. A: Stably incorporated
monolayers in full medium. Luciferase activity is measured in cells that we
wounding. Luciferase activities normalized by cell protein are shown as me
cells are wounded and incubated in DMEMwith or without 10% FCS for 3 and
C: Confluent BM-Lux cells are wounded and incubated in DMEM with 10%
*P  0.05. D: Confluent quiescent BUMPT cells are wounded and incubated
extracts are immunoblotted for phospho-Smad2 and Smad2. E: After overn
g/mL sodium selenite, and 4 g/mL dexamethasone, subconfluent BUMPT cells ar
for 1 hour. SDS extracts of cells are immunoblotted for phosphorylated and total Smproximal tubule cells to produce and release TGF- to
increase TGF- signaling. In view of complexities inher-
ent to studying IRI in vivo, we used cell culture models to
study these mechanisms. TGF- signaling in cultured
proximal tubule cells was autoregulated by cell density.
Signaling was suppressed during confluent growth ar-
rest, but increased again when dedifferentiation, migra-
tion, and proliferation were induced by wounding.3 By
using a bioluminescent assay for active TGF-, we inves-
tigated if the signaling modulations corresponded to vari-
ations in the levels of secreted TGF- in growth medium.
Although the assay was highly sensitive, as reported,40 the
levels of activity in conditioned media were at or less than
the lowest levels of detection, and there were no differences
between subconfluent, confluent, or wounded cultures
(data not shown). Nevertheless, inclusion of neutralizing
TGF- antibodies in the medium suppressed TGF- signal-
ing in subconfluent or wounded cultures, reflected by re-
duced activity of the TGF-–responsive p3TP-Luc reporter
and attenuated C-terminal phosphorylation of Smad23 (data
not shown). These results implied that high TGF- signaling
that was constitutive in subconfluent cells or triggered by
wounding of confluent cultures was caused by nascent
TGF- that was produced on the cell surface, and then was
bound to the receptor before internalization by endocytosis,
but was not released into the medium in active form. We
inferred that neutralization of nascent TGF- occurred on
the cell surface. These considerations explained our failure
to detect active TGF- in the conditioned medium.
During normal conditions of renal perfusion with blood,
proximal tubule cells are exposed to plasma and the normal
variations of cellular signaling that take place under these
physiological circumstances are governed, in part, by plas-
ma-derived factors. However, after acute injury with atten-
c TGF- reporter BUMPT cells (BM-Lux cells) are grown to be confluent
dium with serum (10% FCS) or without serum (FCS free) for 6 hours after
relative fold change (n  6). *, **P  0.01. B: Confluent quiescent BUMPT
. SDS extracts are immunoblotted for phospho-Smad2 (S465/467) and Smad2.
FCS (R-FCS) or C-FCS with or without FCS lipid extract for 6 hours (n  4).
um with R-FCS, C-FCS, FCS lipid extract, or 10 mol/L LPA for 6 hours. SDS
um starvation in DMEM/F-12 with supplements of 5 g/mL transferrin, 6.7p3TP-Lu
re in me
an  SE
6 hours
regular
in medi
ight sere treated with medium with 10% FCS, without FCS, or with FCS lipid extract
ad2. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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and the coagulation cascade is triggered in the injured
tubule-vascular microenvironments.29 To reproduce such
contexts of in vivo injury in tissue culture, we used a wound
model in which most (up to approximately 90%) of conflu-
ent, quiescent, and differentiated cells was removed by
crush injury and the regenerative response of remaining
cells was studied in a highly reproducible manner.39
Wounding was performed in the presence or absence of
serum, instead of plasma, to mimic the in vivo context of
injury and activation of platelets and the coagulation cas-
cade in the microcirculation. Wound-stimulated TGF- sig-
naling by confluent BUMPT cells in vitro was suppressed in
serum-free medium, shown by p3TP-Luc reporter activity
(Figure 2A) and decreased C-terminal phosphorylation of
Smad2 (Figure 2B). Serum has abundant TGF-, but most
of the peptide is latent and complexed with large proteins.45
To identify serum factors responsible for TGF- signaling,
we fractionated serum by charcoal stripping. Wound-in-
duced TGF- signaling was markedly reduced in medium
with stripped serum (Figure 2, C and D), and the addition of
lipids extracted from serum or charcoal absorbent re-
stored the ability of charcoal-stripped FCS to sustain
wound-induced TGF- signaling (Figure 2, C and D).
Figure 3. LPA is the major bioactive serum-borne lipid that stimulates TGF-
signaling. A: FCS-starved BUMPT cells are treated with 10 mol/L LPA, 10
mol/L S1P, or 10 mol/L sphingosylphosphorylcholine (SPC) for 45 min-
utes. Cell lysates are immunoblotted for phospho-Smad2 and Smad2. B:
Confluent BM-Lux cells are wounded and treated with 10% regular FCS
(R-FCS) or C-FCS with or without 10 mol/L S1P for 6 hours (n  6). *P 
0.05. C: Confluent BM-Lux cells are wounded and treated with R-FCS or
C-FCS with or without 10 mol/L LPA for 4 hours (n  6). *P  0.01, **P 
0.05. D: Confluent BM-Lux cells are wounded in 10% FCS with or without 10
mol/L HLZ-56 (HLZ) for 6 hours (n  6). *P  0.05. GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase.Moreover, the addition of the lipid extracts to serum-starved BUMPT cells increased the C-terminal phosphor-
ylation of Smad2 (Figure 2E) and reporter activity from
p3TP-Luc (data not shown). Because amphophilic serum
lipids, such as LPA and S1P, can produce pleiotropic
cellular effects by activating GPCR, we tested LPA, S1P,
and another serum lipid (the GPCR ligand sphingosyl-
phosphorylcholine) for their ability to transactivate TGF-
signaling. LPA and S1P, but not sphingosylphosphoryl-
choline, increased the levels of phospho-Smad2 when
they were added to serum-starved BUMPT cells (Figure
3A), and the addition of LPA to charcoal-stripped FCS
Figure 4. LPA stimulates TGF- signaling in a dose- and time-dependent
manner. A: Overnight FCS-starved subconfluent BUMPT cells are treated with
1.25, 2.5, 5, and 10 mol/L LPA in FCS-free medium for 1 hour. Cell lysates are
immunoblotted for phospho-Smad2 and Smad2. B: Overnight FCS-starved sub-
confluent BUMPT cells are treated with 10 mol/L LPA in FCS-free medium for
15 minutes (0.25 hours), 30 minutes (0.5 hours), and 1, 2, and 6 hours. Cell
lysates are immunoblotted. C: Subconfluent BUMPT cells are serum starved
overnight, pre-incubated without or with 2 mol/L SB431542 in serum-free
medium, and treated with 10 mol/L LPA for 1 hour. Cells are extracted for
Western blot analysis. D: BUMPT cells grown on a membrane filter are pre-
incubated with 10 g/mL TGF-–neutralizing antibody (TGF- Ab) or nonim-
mune IgG in FCS-free medium overnight, and then treated with 10 mol/L LPA
for 1 hour. SDS extracts are immunoblotted for phospho-Smad2 and Smad2. E:
Subconfluent BM-Lux cells with stably transfected p3TP-Luc are serum starved
overnight, pre-incubated without or with 2 mol/L SB431542 (SB) in serum-free
medium, and then treated with 10mol/L LPA for 4 hours. Cells are extracted for
luciferase assay (n  7). * P  0.01. F: Serum-starved BUMPT cells with stably
incorporated (CAGA)12 X TGF- reporter are pre-incubated with 2 mol/L
SB431542 (SB) and treated with 10 mol/L LPA for 6 hours in serum-free
medium. Luciferase activity is measured, and the values are normalized by cell
protein (n  3). *P  0.05. GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase.
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phosphorylation (Figure 2D). LPA was more potent than
S1P in this respect (Figure 3, B and C), and HLZ-56, a
pan-LPA receptor antagonist,46 partially, but signifi-
cantly, attenuated wound-induced p3TP-Luc reporter ac-
tivity in the presence of serum (Figure 3D). Therefore, we
devoted further experimentation to this phospholipid.
LPA treatment of BUMPT cells increased TGF- sig-
naling in a dose- and time-dependent manner, shown by
phosphorylation of Smad2 levels (Figure 4, A and B) and
stimulation of p3TP-Luc activity (data not shown). LPA-
stimulated Smad2 phosphorylation was inhibited by
Figure 5. LPA stimulates TGF- signaling in mouse proximal tubule primary
cultures and cultured human proximal tubule cell lines. A: First-passage mouse
primary culture of proximal tubule cells grown overnight in serum-free DMEM/
F-12 with supplements of 5 g/mL transferrin, 6.7 g/mL sodium selenite, and
4 g/mL dexamethasome. SDS extracts from the indicated time of 10 mol/L
LPA treatment are immunoblotted for Smad2. B and C: Subconfluent human
proximal tubule cell lines, HK2 and HPCT, are treated with 10 mol/L LPA after
serum starvation overnight. Cell lysates are extracted at the indicated times and
immunoblotted. As shown for BUMPT cells in Figure 4, LPA treatment results in
increased phosphorylation of Smad2 in a time-dependent manner, after a vari-
able chronology of phospho-Smad2 increase and a subsequent decrease.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.Figure 6. LPA-induced TGF- activation is via the LPA2 receptor. A: Serum-
starved subconfluent BUMPT cells are pre-incubated with 10 mol/L HLZ-56 for
3 hours and treated with 10 mol/L LPA for 1 hour. Cell lysates are subjected to
Western blot analysis. B:mRNAs are extracted from confluent, subconfluent, and
6 hours of wound BUMPT cells, and analyzed by quantitative PCR. The mRNA
fold change over confluent is shown as mean  SE (n  4). For comparisons
between LPAs 1 and 2 and LPAs 3, 4, and 5, (P 0.01). C: Subconfluent BUMPT
cells with stably transfected LPA2 shRNA or scrambled control are serum starved
overnight and treated with 10 mol/L LPA in serum-free medium. Cells are
extracted for Western blot analysis at indicated times. GAPDH, glyceraldehyde-
3-phosphate dehydrogenase.
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treatment with TGF-–neutralizing antibody (Figure 4, C
and D). As previously reported, Smad3 was much less
abundant in BUMPT cells and Smad3 C-terminal phos-
phorylation was seen by using Western blot analysis only
after stimulation with TGF-.3 However, compared with
the marked LPA-stimulated increase of p3TP-Luc re-
porter activity (Figure 4E), we observed weaker, but sig-
nificant, stimulation of (CAGA)12 X Smad3 reporter ac-
tivity by LPA (Figure 4F), and both activities were
inhibited by TGF- receptor antagonist, SB431542 (Fig-
ure 4, E and F). Stimulation of TGF- signaling by LPA in
BUMPT cells was confirmed by signals elicited from sta-
bly transfected Smad2-responsive 2 X ARE-Luc reporter
(data not shown). Stimulation of TGF- signaling by LPA
was also demonstrated in primary cultures of mouse
proximal tubule cells and in cultured human kidney prox-
imal tubule cell lines HK2 and HPCT (Figure 5, A–C).
LPA-Induced TGF- Activation Is via an LPA2
Receptor
It is known that LPA produces pleiotropic effects in cells
through interactions with multiple receptors and diver-
gent effecter pathways. We first determined that LPA-
mediated TGF- activation was mediated specifically
through its receptor(s). BUMPT cells were treated with 10
mol/L LPA, with or without the pan-LPA competitive
receptor inhibitor, HLZ-56.46 In the presence of HLZ-56,
LPA-induced C-terminal phosphorylation of Smad2 was
markedly attenuated (Figure 6A). These impressive ef-
fects of HLZ-56 on Smad2 phosphorylation contrasted
with only partial inhibition of wound-stimulated p3TP-Luc
reporter activity by HLZ-56. This was likely to be ex-
plained by the responsiveness of this reporter to nonca-
nonical as well as canonical TGF- signaling. The non-
canonical pathways could be stimulated individually,
separately, and in parallel by several other ligand recep-
tor interactions that were potentially active during cell
wounding.
Wemeasured the expression of LPA receptors in BUMPT
cells by real-time RT-PCR. Although mRNAs for all recep-
tors, LPA1 through LPA5, were expressed, LPA1 and LPA2
were predominant in subconfluent, confluent, and wounded
cells (Figure 6B). Because of their relative abundance, we
Figure 7. LPA induces TGF- activation via Gq-mediated Rho/ROCK path-
way. A: After serum-starved subconfluent BUMPT cells are pre-incubated
with 10 mol/L BIM46174 (BIM) or 0.2 g/mL pertussis toxin (PTX) for 3
hours, cells are treated with 10 mol/L LPA for 1 hour. Cell lysates are
subjected to Western blot analysis. B: BUMPT cells stably transfected with
(CAGA)12 X-Luc reporter are treated as described for Figure 7A. Cell extracts
after 6 hours of LPA treatment are measured for luciferase activity (n  3).
*P  0.01. C: BUMPT cells are transfected with G C-terminal minigenes or
a scrambled control (GiR) using Fugene HD reagent at a 2:5 ratio of DNA:
FuGene. After 24 hours, cells are treated with 10 mol/L LPA in serum-free
medium for 1 hour. SDS extracts of cells are immunoblotted for Smad2. D:
BUMPT cells are transfected with Gq minigene or control. After 48 hours,
cells are treated with 10 mol/L LPA for 1 hour in serum-free medium. SDS
extracts of cells are immunoblotted for Smad2. E and F: BUMPT cells are
grown and serum starved as in Figure 7A. Cells are pre-incubated without or
with 2 g/mL Rho inhibitor C3 transferase or 20 mol/L Y-27632 for 2 hours,
and then treated with 10 mol/L LPA for 1 hour. The SDS extracts of cells are
immunoblotted. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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BUMPT cells. Ki16425, a selective antagonist of LPA1
and LPA3 receptors,47 did not inhibit TGF- signaling
induced by LPA, as shown by phosphorylation of Smad2
levels (data not shown). Suspecting that LPA2 receptors
were responsible for TGF- activation, we tested the ef-
fects of LPA in cultures of BUMPT cells expressing
shRNA specific for LPA2. Western blot analysis con-
firmed that BUMPT cell LPA2 protein expression was
reduced after transduction with LPA2 shRNA compared
with controls with scrambled shRNA (Figure 6C). LPA-
induced C-terminal Smad2 phosphorylation was inhibited
by LPA2 shRNA without affecting total Smad2 levels (Fig-
ure 6C), suggesting that LPA2 was the major receptor
involved in LPA-induced TGF- activation.
LPA Activates TGF- Through a Gq-Mediated
Rho/ROCK Pathway
Next, we investigated whether LPA effects on TGF- sig-
naling were mediated by specific G proteins coupled to
the receptors. BIM46174 is a pan inhibitor that interferes
with the G/G protein complex by targeting G sub-
units.48 BIM46174, at a 10 mol/L concentration, inhib-
ited LPA-mediated TGF- signaling, shown by Smad2
phosphorylation (Figure 7A) and by (CAGA)12 X Smad3
reporter activity (Figure 7B). LPA effects are generally
coupled to G proteins, Gi, Gq, G12/13, and Gs.
Pertussis toxin that inhibits GPCR signaling through ADP-
ribosylation of Gi/o subunits49 had no effects on LPA-
stimulated Smad2 phosphorylation or (CAGA)12 X
Smad3 reporter activity (Figure 7, A and B), negating a
role for Gi/Go. To determine which G-protein subunit was
involved in LPA-induced TGF- activation, G C-terminal
minigene vectors were transfected individually into
BUMPT cells. C-terminal G peptides selectively block
G-protein binding sites on GPCR.50 LPA-induced Smad2
phosphorylation was blunted by the Gq/11 minigene,
but not by others (Figure 7, C and D). Because signal
transduction by LPA via Gq includes activation of the
Rho/Rho-associated protein kinase (ROCK) and phos-
Figure 8. LPA induces integrin v6-mediated latent TGF- activation. A:
Serum-starved subconfluent BUMPT cells are treated with 6.5 ng/mL latent
TGF- with or without 10 mol/L LPA for the indicated times. Cell lysates are
subjected to Western blot analysis for phospho-Smad2 and Smad2. B: Serum-
starved subconfluent BM-Lux cells with stably transfected p3TP-Luc are
extracted for luciferase activity after 6 hours of treatment with or without
latent TGF- (L-TGF-) and LPA, as in Figure 8A (n  5). *P  0.05. C:
Serum-starved subconfluent BUMPT cells are pre-incubated with Gly-Arg-
Gly-Asp-Ser (GRGDS) or control peptide Gly-Arg-Gly-Glu-Ser (GRGES) at
the indicated concentration for 3 hours, and then treated with 10 mol/L LPA
for 1 hour. SDS extracts of cells are immunoblotted for phospho-Smad2 and
Smad2. D: BUMPT cells are plated and serum starved, as previously described.
After cells are pre-incubated with 100 mol/L Arg-Gly-Asp-Leu-Gly (RGDLG) or
control peptide Arg-Gly-Glu-Leu-Gly (RGELG) for 3 hours, they are treated with
10 mol/L LPA for 1 hour. SDS extracts of cells are immunoblotted for phospho-
Smad2 and Smad2. E: After subconfluent BUMPT cells are incubated with 10
g/mL neutralizing 6.3G9 v6 monoclonal antibody (v6 Ab) or nonimmune
IgG in serum-free medium overnight, they are treated with 10 mol/L LPA for 1
hour. SDS extracts of cells are immunoblotted for phospho-Smad2 and Smad2.
F: Confluent growth-arrested BUMPT cell monolayers are wounded, and the
remaining cell strips are allowed tomigrate and proliferate in 10% FCS DMEM for
the indicated times. SDS extracts of cells are immunoblotted under nonreducing
conditions for 6 integrin with ch2A1 antibody and under reducing conditions
for phospho-Smad2 and Smad2. Ctrl, confluent control; GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase.
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ined the effects of the protein kinase C inhibitor Gö 6983
on LPA-induced TGF- activation. Gö 6983 had no effect
on LPA-induced Smad2 phosphorylation and p3TP Luc
reporter activity, excluding phospholipase C/protein ki-
nase C involvement (data not shown). We hypothesized
that LPA could signal via RhoA and Rho kinase to induce
TGF- activation. When we stimulated BUMPT cells with
10 mol/L LPA in the presence of 2 g/mL of exoenzyme
C3 transferase, a specific RhoA/B/C inhibitor, C-terminal
phosphorylation of Smad2, was attenuated (Figure 7E).
Moreover, we found that Y-27632, an inhibitor of ROCK,51
also attenuated the C-terminal phosphorylation of Smad2
induced by LPA (Figure 7F). Taken together, these re-
sults suggested that LPA-induced TGF- activation was
mediated through the Rho/ROCK pathway.
LPA Induces Integrin v6-Mediated Latent
TGF- Activation
Rho/ROCK signaling has been implicated in the activa-
tion of v6 integrin.18 To identify a possible integrin-
dependent mechanism for LPA-induced TGF- activa-
tion, we determined whether LPA could activate the latent
form of TGF- in BUMPT cells. In the presence of 6.5
ng/mL latent TGF-, Smad2 C-terminal phosphorylation
was increased compared with controls without latent
TGF- (Figure 8A). However, a further robust increase
was induced in response to 10 mol/L LPA, and sus-
tained C-terminal phosphorylation was seen even after a
prolonged interval of 4 hours after LPA treatment (Figure
8A). Similar observations were made using the p3TP-Luc
reporter (Figure 8B). These data showed that BUMPT
cells converted latent TGF- to the active peptide under
basal conditions and responded to LPA by further in-
creasing the rate of activation. The latent TGF- peptide,
LAP1, contains the RGD motif that is a binding site for
integrins.10 Therefore, we examined whether access to
RGD binding sites governed LPA-induced TGF- activation
in BUMPT cells. Gly-Arg-Gly-Asp-Ser peptide, which blocks
integrin binding to RGD sequences, decreased LPA-in-
duced Smad2 phosphorylation comparedwith Gly-Arg-Gly-
Glu-Ser control peptide (Figure 8C). Similarly, Arg-Gly-Asp-
Leu-Gly, a peptide based on the TGF--LAP sequence, but
not the mutant peptide Arg-Gly-Glu-Leu-Gly, inhibited LPA-
stimulated Smad2 phosphorylation (Figure 8D).
Two models have been proposed for integrin-medi-
ated activation of latent TGF-, which includes enzymatic
cleavage of latent TGF-1 and mechanical conforma-
tional change of latent TGF-.9,52 Recent studies sug-
gested that conformational change induced in the
TGF-1 prodomain by tensile forces pulling on bound
v6 is sufficient to release the active peptide.53 Matrix
metalloproteinases are also implicated in TGF- activa-
tion. To investigate this hypothesis, we used the general
matrix metalloproteinase inhibitor, GM6001. Treatment
with 5 to 50 mol/L of GM6001 had no effect on phospho-
Smad2 levels in LPA-stimulated BUMPT cells (data not
shown). We also found that a protease inhibitor cocktail
with 1 mmol/L aminoethylbenzenesulphonyl fluoride, 50
mmol/L -aminocaproic acid, 0.2 mmol/L gabexate, 0.2mmol/L GM6001, 0.01 mmol/L leupeptin, 0.1 mmol/L D-
phenylalanyl-L-prolyl-L-arginine chloromethyl ketone
(PPACK), and 1 mmol/L tosyl arginine methyl ester
(TAME) also could not inhibit LPA-induced TGF- signal-
ing (data not shown). The epithelial integrin v6 could
Figure 9. LPA stimulates TGF-–dependent production of PDGF-B and
CTGF. A: Subconfluent BUMPT cells are serum starved in DMEM/F-12 with
supplements of 5 g/mL transferrin, 6.7 g/mL sodium selenite, and 4 g/mL
dexamethasone overnight. Cells are pre-incubated with 1 mol/L SB431542
(SB) or vehicle for 2 hours, then treated with or without 10 mol/L LPA for
1 hour. RNA is extracted for real-time PCR analysis (n  4). *P  0.05. B:
Subconfluent BUMPT cells are incubated in defined medium overnight, as
described for Figure 9A, in the presence of vehicle only, 10 mol/L LPA, or
10 mol/L LPA plus 1 mol/L SB431542. Cells are extracted with SDS buffer.
Medium is collected and concentrated using 10-kDa cutoff centrifugal filters
and reconstituted with SDS buffer. Cells and medium are immunoblotted for
CTGF. C: Concentrated media from BUMPT cells, as described in B, are
subjected to PDGF-B analysis by enzyme-linked immunosorbent assay and
normalized to total protein extracted from the cells (n  3). *P  0.05.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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activity by contractile cellular forces. To determine
whether integrin v6 was involved in LPA-induced RGD
motif–mediated activation of TGF-, we incubated
BUMPT cells with 10 g/mL neutralizing 6.3G9 anti-v6
monoclonal antibody before treatment with LPA. The
basal level and LPA-induced C-terminal phosphoryla-
tion of Smad2 was significantly decreased by the an-
tibody, demonstrating that both autocrine TGF- sig-
naling under basal conditions and induced activation
by LPA was v6 integrin dependent (Figure 8E). The
6 subunit associates exclusively with the v subunit to
form the functional v6 integrin. Therefore, we used
an antibody against the integrin 6 subunit to evaluate
protein levels of integrin v6. The levels of 6 integrin
protein were low in subconfluent cells and increased
when cells reached high density at confluence (data
not shown). Notably, the integrin was further induced
substantially by 6 hours of wounding to remove ap-
proximately 90% of cell mass but returned to levels
even lower than confluent nonwounded cells by 24
hours (Figure 8F), when they were again subconfluent
and growing.
LPA Stimulates TGF-–Dependent Production
of PDGF-B and CTGF mRNA and Peptide
TGF- can induce PDGF-B and CTGF expression.54–56
Consequently, we examined if LPA-stimulated TGF-
signaling could induce the production of these profi-
brotic peptides in cultured proximal tubule cells. Incu-
bation of BUMPT cells with LPA led to rapidly in-
creased expression of mRNA for PDGF-B and CTGF,
increased cellular content of CTGF peptide, and sub-
stantial secretion of both peptides into the culture me-
dium (Figure 9, A–C). These actions of LPA were sub-
stantially blunted by treatment with TGF- type I
Figure 10. LPA2 and 6 integrin protein levels are increased during renal
ischemia-reperfusion injury. Rat kidney SDS extracts, as described for Figure
1A, are immunoblotted for 6 integrin and LPA2. The TGF-1 blot is the same
as shown in Figure 1A. Ctrl, control; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.receptor antagonist, SB431542 (Figure 9, A–C).LPA2 and the v6 Integrin Protein Levels Are
Increased during Renal Ischemia-Reperfusion
Injury in Rats
Finally, we investigated the possible relevance of LPA2
receptors and v6 integrin to renal injury in vivo. Western
blot analyses of SDS extracts from the outer stripe of the
outer medulla of kidneys reperfused after ischemia
showed augmented expression of LPA2 receptor protein
by 1 day of reperfusion that increased thereafter, becom-
ing abundant relative to the basal state by 14 days, in
effect following a pattern that paralleled the increase of
TGF- and phospho-Smad2 (Figure 10). The expression
of 6 integrin protein also increased rapidly by 8 hours of
reperfusion, and after subsequent decline, increased
again by 14 days (Figure 10). Treatment of rats with
TGF- type I receptor antagonist, SD208, had no effect
on IRI-induced expression of LPA2, but decreased that of
6 integrin (Figure 10).
Discussion
We demonstrate that LPA stimulates the production and
secretion of fibrogenic peptides, PDGF-B and CTGF, by
cultured kidney proximal tubule cells through a mecha-
nism that transactivates TGF-. TGF- transactivation by
LPA is mediated by LPA2 receptor signaling transduced
by the G-protein, Gq, and is dependent on v6 integ-
rin-dependent conversion of latent TGF- to the active
peptide. We also found that high TGF- signaling and
tubulointerstitial fibrosis that follows ischemic acute kid-
ney injury is accompanied by increased LPA2 receptor
and by enhancement of v6 integrin expression and
overproduction of PDGF-B and CTGF by tubules associ-
ated with fibrosis. All of these pathological events occurred
co-incidentally within the same time frame. The critical role
played by TGF- signaling in tubule overproduction of
PDGF-B and CTGF was shown by treatment with a TGF-
type I receptor antagonist that reversed the increased ex-
pression of v6 integrin and fibrogenic peptide produc-
tion. The net result was amelioration of fibrosis.
Experiments on cultured proximal tubule cells pro-
vided the more mechanistic information on the serial
steps of LPA-induced signal transduction. In addition,
these studies showed that v6 integrin-mediated con-
version of latent TGF- required signaling through Rho
and ROCK. The specificity of signaling steps involved in
LPA-induced secretion of PDGF-B and CTGF was indi-
cated by shRNA knockdown of LPA2, peptide minigene
inhibition of Gq, antagonism of Rho and ROCK, and
blockade of LAP binding to v6 integrin, TGF-–neutral-
izing antibodies, and type I receptor-specific inhibition of
TGF- signaling.
PDGF-B and CTGF activate kidney pericytes and fibro-
blasts, causing proliferation, collagen synthesis, and fi-
brosis.57–59 These peptides are produced in increased
amounts by tubules when they regenerate during reper-
fusion after ischemic injury.4,60 If repair of ischemic dam-
age is complete, increased production of PDGF-B and
CTGF should subside, provided that tubules redifferenti-
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subset of tubules does not recover normally, fails to red-
ifferentiate, and continues to signal along pathways that
were initiated in response to the needs of epithelial re-
generation.3,6 Unlike normal proximal tubule epithelium,
such tubules without differentiated features are immuno-
reactive with antibodies to vimentin, an intermediate fila-
ment protein expressed by surviving cells as they dedif-
ferentiate and proliferate after injury.6,61 These cells with
the phenotype of failed differentiation show persistently
high TGF- signaling, abnormally low phosphatase and
tensin homolog (PTEN) levels, and high Jun N-terminal
kinase signaling.6 As our current data show, tubules with
this phenotype that are surrounded by proliferating myo-
fibroblasts and fibrosis6 continue to express high TGF-
and PDGF-B and CTGF. More important, all of these
pathological alterations are ameliorated by treatment with
a TGF- type I receptor antagonist, SD2083,6 (and our
current data). The production by diseased tubules of
three fibrogenic peptides (TGF-, PDGF-B, and CTGF)
concurrently raises issues of precedence and relative
importance of individual peptides in the pathogenesis of
fibrosis. As recently indicated, TGF- could be cooper-
ating with both CTGF and PDGF-B to promote their fibro-
genic actions.56–58
LPA mediated v6 integrin-dependent transactiva-
tion of TGF- may be relevant to the kidney pathophys-
iology that develops during reperfusion after IRI and
fibrosis thereafter. This is suggested by increased ex-
pression of LPA2 receptor and 6 integrin during reper-
fusion after a time course similar to that of TGF-1 (Figure
10). Notably, because fibrosis developed by 2 weeks of
reperfusion, increases of TGF- and phospho-Smad2,
and those of LPA2 and 6 integrin, did not subside, as
should happen with full recovery, but increased substan-
tially (Figure 10). The expression of CTGF also followed a
similar time course. As assessed by IHC, PDGF-B ex-
pression was also consistent with such a time scale. The
temporal congruency of LPA2 and integrin expression
with that of TGF- and profibrotic peptides after IRI is
circumstantial evidence, suggesting that these altera-
tions were causally interrelated during the disease pro-
cess in vivo, as demonstrated by experiments using cul-
tured cells. Pharmacological antagonism of TGF-
receptor with SD208 did not modify the IRI-induced in-
crease of TGF-1 protein in the kidney. However, it de-
creased TGF- signaling, assessed by Smad2 phosphor-
ylation and nuclear localization of Smad2, corrected the
elevations of PDGF-B and CTGF expression (Figure 1),
and ameliorated the tubulointerstitial fibrosis caused by
IRI.3,6 Together, these data provide a degree of internal
consistency, suggesting that our current observations,
made in vivo, were meaningful with respect to the disease
process. However, we do not understand why SD208
treatment was able to reverse the IRI-induced expression
of 6 integrin, but not that of the LPA2 receptor. It seems
possible that increased expression of 6 integrin may
occur as a consequence of the maladaptive increase of
TGF- signaling in the injured kidney because it was
ameliorated by SD208. On the other hand, increasedLPA2 could be related to another injury-associated
mechanism that is TGF- independent.
The actions of v6 integrin to activate latent TGF- are
well recognized. However, the role played by GPCR as a
proximal signaling trigger that leads to the integrin step has
only recently been identified by the work of Jenkins, Shep-
pard, and colleagues.15,18 Protease activated receptor
(PAR)1-mediated thrombin-initiated GPCR signaling led to
v6 integrin-dependent transactivation of TGF- in models
of acute lung injury including bleomycin-induced pulmo-
nary damage, and LPA-initiated LPA2-mediated GPCR
signaling caused v6 integrin-dependent transactiva-
tion of TGF- in bleomycin-induced pulmonary fibro-
sis.15,18 The signaling pathway was traced in detail by Xu
et al18 from the LPA2 receptor to v6 integrin via Gq,
Rho, and Rho kinase. Our study finds that the signaling
mechanism is similar in proximal tubule cells and extends
the observations by connecting this intricate pathway to
cellular expression and secretion of fibrogenic peptides,
PDGF-B and CTGF. More limited observations connect
LPA-initiated TGF-–dependent expression of CTGF in
cultured myocytes.62 Although Ma et al17 identified v6
integrin-mediated TGF-–dependent fibrosis in a model
of ureteral obstruction, they also found strong evidence
for an integrin and TGF-–independent mechanism; in-
terestingly, the TGF-–independent mechanism was ini-
tiated by another GPCR ligand, angiotensin II. More in-
terestingly, Chen et al21 reported that the profibrotic
actions of angiotensin II are related to transactivation of
epidermal growth factor receptor and subsequent acti-
vation of an extracellular signal–regulated kinase–medi-
ated pathway that increased the production of TGF-. On
the other hand, Pradere et al22 found that fibrosis in the
ureteral obstruction model was related to increased pro-
duction of LPA and signaling via the LPA1 receptor. To-
gether with other evidence that has connected GPCR li-
gands LPA, thrombin, and angiotensin II to TGF-
production and/or renal fibrosis, we suspect that the analy-
sis of GPCR-based signaling mechanisms that cause
TGF- activation or overproduction will be complex. This is
made more difficult by multiple GPCR ligands and recep-
tors, receptor redundancy, and interactions with other sig-
naling mechanisms. Indeed, we cannot exclude other
GPCR ligands, such as S1P, that have protective activity
during the acute phase of IRI,30 which may have late effects
to modify the actions of LPA. Based on these consider-
ations, it would appear that interventions based on a single
ligand or a single class of receptor are unlikely to yield
conclusive information immediately relevant to the treatment
of fibrosis. A full understanding of what actually happens in
the diseased environment will require the detailed delinea-
tion of signaling by multiple classes of GPCR and G pro-
teins.
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